| 1. |
|
|
| 2. |
- Brenner, B, et al.
(författare)
-
Thrombophilia and pregnancy complications
- 2004
-
Ingår i: Thromb Haemost. ; 92:4, s. 678-81
-
Tidskriftsartikel (refereegranskat)abstract
- The implications of currently available data on the association of gestational vascular complications with thrombophilia are presented in this consensus report. Screening is recommended for women with the following previous complications: fetal loss including three or more first trimester loss, two or more second trimester loss, or any stillbirth; early, severe or recurrent preeclampsia and severe intrauterine growth restriction. Maternal antithrombotic therapy is currently evaluated in women with thrombophilia and previous complications.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Reardon, A, et al.
(författare)
-
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
- 2009
-
Ingår i: British Journal of Cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 101:12, s. 1995-2004
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). CONCLUSION: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. British Journal of Cancer (2009) 101, 1995-2004. doi: 10.1038/sj.bjc.6605411 www.bjcancer.com Published online 10 November 2009 (C) 2009 Cancer Research UK
|
|
| 7. |
- Schlegel, M. C., et al.
(författare)
-
Pathway of a damaging mechanism-Analyzing chloride attack by synchrotron based X-ray diffraction
- 2015
-
Ingår i: Solid State Sciences. - : Elsevier Masson SAS. - 1293-2558 .- 1873-3085. ; 44, s. 45-54
-
Tidskriftsartikel (refereegranskat)abstract
- Typically, the changes of the phase compositions due to the chemical attack are studied in-situ only by chemical analysis or microscopy. In this study, the chloride transport and binding in the cement matrix in different cementitious materials was analyzed by synchrotron based X-ray diffraction (SyXRD) and energy dispersive X-ray spectroscopy (EDX). Sample materials consisting of cement paste were embedded in high concentrated sodium chloride solution over different time spans. Afterwards, the phase and chemical compositions were determined. The high spatial resolution and the information about the chloride distribution offer a detailed view of chloride binding in the cement matrix and allow the conclusions about the degradation mechanisms. The results are discussed related to the influence of different supplementary cementitious materials on the damaging mechanism. © 2015 Elsevier Masson SAS.
|
|
